15.07.2010 • NewsportfolioCarbon BlackEvonik

Evonik Establishes Independent Carbon Black Company

Evonik Industries is reorganizing its carbon black activities. On July 1, Evonik Carbon Black was founded as a legally independent management company under the umbrella of Evonik Industries. CEO is Jack Clem and Rainer Wobbe will take over the position of the CFO. The operational headquarters of the company, currently in Frankfurt, will move to Hanau-Wolfgang, Germany, on Oct. 1. The product portfolio and the relationship to the customer will not be affected by the spin-off. Evonik, the second largest manufacturer worldwide, produces carbon black at 17 sites in 12 countries on four continents. In the last fiscal year some 1,700 employees generated sales of about €1 billion.

Having spun off the carbon black business, Evonik is currently examining three strategic options to develop its business further. The possibilities extend from optimization as an independent market unit, through a partnership solution, to sale of the business. One of these three options will be decided upon before the end of the second half of the year.

Company

Logo:

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.